Stem Cell Therapies in Clinical Trials: Progress and Challenges.

Area of Science:

• Regenerative Medicine
• Stem Cell Biology
• Immunology

Background:

• Clinical trials increasingly utilize diverse stem cell types for regenerative medicine.
• Current safety data from autologous and allogeneic stem cell transplants indicate a low incidence of adverse events.
• Administered stem cells often exhibit transient persistence, primarily exerting trophic effects on immune and inflammatory processes.

Purpose of the Study:

• To review the current landscape of stem cell applications in regenerative medicine.
• To highlight the safety profile and therapeutic mechanisms of stem cell products.
• To discuss approved stem cell therapies and ongoing clinical trial progress.

Main Methods:

• Review of clinical investigations and regulatory approvals for stem cell products.
• Analysis of safety reports from stem cell transplantation studies.
• Examination of the pharmacokinetic and pharmacodynamic properties of administered stem cells.

Main Results:

• Few safety concerns reported for autologous and allogeneic stem cell transplants.
• Transient presence of administered cells observed, with significant trophic effects.
• Successful regulatory approvals for specific stem cell therapies, including limbal stem cells for ocular burns and mesenchymal stem cells for graft-versus-host disease.

Conclusions:

• Stem cell therapies are advancing in regenerative medicine with a generally favorable safety profile.
• Trophic functions, rather than long-term engraftment, appear to be a key mechanism for many stem cell applications.
• Approved therapies and ongoing trials demonstrate the clinical utility and potential of stem cells for treating various diseases.